About our Cardio-Renal-Metabolic Diseases efforts
Building on our legacy of innovative treatments for a range of cardiovascular, renal and metabolic conditions, our R&D strategy takes a holistic view of the needs of people with metabolic diseases such as diabetes, who often have multiple, related conditions. We are pursuing the next wave of innovative medicines for obesity, kidney and liver diseases – including metabolic dysfunction-associated steatohepatitis (MASH).
Selection of projects in February 2024
Phase 1 studies are usually designed with an emphasis on the assessment of safety and tolerability of an investigational drug in a small group of people for the first time. It can include healthy participants or participants with the disease.
GLP-1/FGF21 agonist
NPY2r agonist
Anti-fibrotic agent
Phase 2 studies are usually designed to begin to evaluate the efficacy of an investigational drug in a higher number of participants with the disease, and often used to obtain dose-ranging information. Safety also continues to be assessed during this phase.
BI 765845
Survodutide (BI 456906)
Avenciguat (BI 685509)
BI 764198
BI 690517 + Empagliflozin
Phase 3 studies are designed to confirm the data of Phase 2 studies for an investigational drug. Large numbers of participants with the disease are generally involved to obtain safety and efficacy data to evaluate the overall benefit-risk relationship of an investigational drug to provide an adequate basis for regulatory approvals. Given the size of these studies and to ensure a representative sample of patients, they are often conducted across several countries.
Empagliflozin / New indication
Survodutide (BI 456906)
Indication abbreviations
CKD: Chronic kidney disease
CSPH: Clinically significant portal hypertension
FSGS: Focal segmental glomerulosclerosis
MASH: Metabolic dysfunction-associated steatohepatitis
HF: Heart failure
MI: Myocardial infarction